The Latest Cardiac and Vascular News
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott’s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip™ for treating mitral regurgitation Results also demonstrate the benefits of Abbott’s TriClip™ for tricuspid regurgitation, […]
BOSTON–(BUSINESS WIRE)–Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30 minutes prior to their percutaneous coronary intervention (PCI) compared to patients who received LV unloading […]
Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the durability of the Symplicity blood pressure procedure DUBLIN and BOSTON, Sept. 18, 2022 /PRNewswire/ — Medtronic plc ( NYSE: MDT), a global leader in healthcare technology, today announced long-term results […]
TAMPA, Fla., Sept. 17, 2022 /PRNewswire/ — The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR). US FDA’s IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated […]
BOSTON, Sept. 17, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR). Results from the CLASP IID […]
Miami-based Physician Specializes in Minimally Invasive Treatments for Peripheral Vascular Disease, Cancer, and Other Diseases HINGHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that […]
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies SANTA CLARA, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in […]
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies. The ENIS-3 trial has achieved >33% of target enrollment (948 patients). The independent data monitoring committee (IDMC) has completed interim analysis and indicated that the trial should continue. The […]
FEops HEARTguide significantly improves efficiency and outcomes of LAAO procedures in the PREDICT-LAA Randomized Clinical Trial GENT, Belgium–(BUSINESS WIRE)–Data from the PREDICT-LAA trial, presented at the Late-Breaking Innovation session at the TCT 2022 convention in Boston shows that Left Atrial Appendage occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result […]
BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking […]
